Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Veltassa
Veltassa
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks
BioSpace
Gilead Sciences
GSK
momelotinib
Roche
Eli Lilly
lebrikizumab
Merck
Zejula
Amgen
Galenica
Veltassa
Cubicin
Flag link:
Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study
Pharmaceutical Business Review
Vifor
hypertension
chronic kidney disease
Veltassa
clinical trials
Flag link:
Galenica to Buy Relypsa for $1.53 Billion
Galenica to Buy Relypsa for $1.53 Billion
TheStreet.com
Galenica
Relypsa
M&A
Veltassa
Flag link:
A Great Month For Relypsa
A Great Month For Relypsa
Seeking Alpha
Relypsa
AstraZeneca
Veltassa
hyperkalemia
ZS-9
Flag link:
3 Big Battles Brewing in Biotech
3 Big Battles Brewing in Biotech
Motley Fool
AstraZeneca
ZS-9
Relypsa
Veltassa
Synergy Pharmaceuticals
plecanatide
Linzess
Ironwood
Allergan
Incyte
Eli Lilly
baricitinib
AbbVie
Humira
Flag link:
Relypsa Rises on Bullish Veltassa Report; AstraZeneca, Sanofi Take Note
Relypsa Rises on Bullish Veltassa Report; AstraZeneca, Sanofi Take Note
Bidness, ETC
Relypsa
Veltassa
AstraZeneca
Sanofi
Flag link:
Relypsa's Veltassa Will Be Embraced By Physicians
Relypsa's Veltassa Will Be Embraced By Physicians
Seeking Alpha
Relypsa
Veltassa
physicians
hyperkalemia
Flag link: